The Food and Drug Administration granted Travere Therapeutics full approval for FILSPARI in focal segmental glomerulosclerosis on April 13, 2026, the drug’s second full approval after a 2023 clearance for IgA nephropathy. Travere’s stock rose 43 percent the next day, closing at $43.81.  The DUPLEX Data Behind a Second Approval FSGS damages the kidney’s filtering […]